The development of chemotherapy for NSCLC over the last 20 years is reviewed, particularly with regard to its palliative effects. New "fourth generation" agents designed to inhibit specific biological pathways thought to be crucial to tumour growth give cause for optimism in the future treatment of NSCLC.
No takes yet. Share an insight, caveat, or question.
M.H. Cullen (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: